This summer, will the influenza in the southern region form a co epidemic trend with the second wave of COVID-19 caused by Omikjon XBB? Since May 2022, the influenza activity in southern provinces of China has continued to increase again, entering a high incidence period in summer, reaching the highest level in the same period of nearly five years, with A (H3N2) subtype as the absolute advantage strain. Zhong Nanshan, an academician of the CAE Member, said at the sub forum of biomedicine and health of the 2023 Great Bay Area Science Forum on the 22nd that the prediction based on the SEIRS model showed that the second wave of COVID-19 epidemic in 2023 in China was mainly caused by the Omikjon XBB series of viruses. The epidemic will peak in mid April, with a peak at the end of May and a peak at the end of June, when the number of infected individuals may reach 65 million per week. A recent study of CDC shows that influenza will return to the regular seasonal epidemic and show an alternate epidemic trend with the COVID-19 epidemic; A co epidemic may occur, but existing evidence has not found a highly prevalent phenomenon. "Monitoring and research data published around the world in the past three years show that the probability of superimposition of novel coronavirus and influenza virus with high prevalence is low, and the co infection rate in normal immune population is also low." An expert familiar with infectious disease monitoring system told First Finance. However, the expert also warned that since the co infection rate will significantly increase among people with low immunity, the co infection of COVID-19 virus and influenza virus will aggravate the body damage and significantly increase the severity rate and mortality rate. In the face of the upcoming flu season, it is still necessary to prioritize prevention and prepare well. Many studies have confirmed that the co infection of COVID-19 and influenza virus will increase the risk of hospitalization and complicate the patient's condition. But a new study released by researchers from the China National Institute for Disease Control and Prevention of Viral Diseases shows that so far, there is no evidence to suggest that influenza and COVID-19 can be highly prevalent simultaneously. At the beginning of 2023, the first influenza season after COVID-19's return to "Class B and Class B", researchers found that novel coronavirus pneumonia and seasonal respiratory pathogens, especially influenza, may co epidemic to varying degrees, but did not form a high epidemic. "These findings may be explained by the ability of influenza A virus and SARS-CoV-2 to block each other in cell research. However, there is still a lack of reliable epidemiological data." At the same time, the research article quoted a research data from a French scholar, saying that the overall proportion of mixed infection of COVID-19 and influenza is 0.7%, which is also at a low level. According to data from the UK Department of Public Health, the majority of co infection cases occur in the elderly, with over half of them potentially leading to death; Another research report shows that the proportion of co infections in children is 3.2%, while in adult patients it is only 0.3%. Therefore, in the above research articles, CDC researchers called for the need to continue to improve the awareness of co infection of COVID-19 and influenza virus, and timely assess the risk of co infection. Dong Xiaoping, the chief expert of virology of CDC, recently introduced to the media such as China First Finance and Economics at a seminar that recent research found that during the COVID-19 pandemic